Trial-Reported Endpoints by Phase Trial Lancet 2021 Phase 2 Duration 26 weeks Population Overweight/obese, no T2D (n=706) Mean Weight Loss 10.8% at 4.5 mg vs 3.0% placebo Trial Lancet 2023 Phase 2 Duration 32 weeks Population T2D + obesity (n=92) Mean Weight Loss 8.1% cagrilintide alone
- [Stability of GLP-1 Receptor Agonist Peptide Formulations Under Refrigerated Conditions]( *International Journal of Pharmaceutical Compounding*, 2022
Benefit 2: Improved Insulin Sensitivity and Blood Sugar Control NNMT activity is linked to insulin resistance and type 2 diabetes
Furthermore, VEGF may also increase the permeability of blood vessels, which might enable the extravasation of plasma proteins and contribute to the formation of a primitive vascular scaffold, thereby potentially promoting the process of angiogenesis
Hence, it is essential to take your healthcare provider onboard before including any new supplement into your diet or making any kind of lifestyle alterations, especially when you are dealing with certain health conditions or are pregnant